[Seite 40↓]


Ahn JY, Tanahashi N, Akiyama K, Hisamatsu H, Noda C, Tanaka K, Chung CH, Shibmara N, Willy PJ, Mott JD. Primary structures of two homologous subunits of PA28, a gamma-interferon-inducible protein activator of the 20S proteasome. FEBS Lett 366, 37-42 (1995)

Ahn K, Erlander M, Leturcq D, Peterson PA, Fruh K, Yang Y. In vivo characterization of the proteasome regulator PA28. J Biol Chem 271, 18237-18242 (1996)

Adler MW. ABC of Aids: Development of the epidemic. BMJ 322, 1226-1229 (2001)

Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-867 (1983)

Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367-380 (1998)

Bayer P, Kraft M, Ejchart A, Westendorp M, Frank R, Rosch P. Structural studies of HIV-1 Tat protein. J Mol Biol 247, 529-535 (1995)

Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335, 123-128 (1990)

Bercovich Z, Kahana C. Involvement of the 20S proteasome in the degradation of ornithine decarboxylase. Eur J Biochem 213, 205-210 (1993)

Berezutskaya E, Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 272, 30135-40 (1997)

Berkhout B, Gatignol A, Rabson AB, Jeang KT. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter. Cell 62, 757-67 (1990)

Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol 62, 61-130 (1996)

Boyer SN, Wazer DE, Band V.E. 7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56, 4620-4624 (1996)

Brockmeyer N. German-Austrian Guidelines for HIV-therapy during pregnancy--status: May/June 1998- common statement of the Deutsche AIDS-Gesellschaft (DAIG) and the Osterreichische AIDS-Gesellschaft (OAG). Eur J Med Res 4, 35-42 (1999)

Cerundolo V, Benham A, Braud V, Mukherjee S, Gould K, Macino B, Neefjes J, Townsend A. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol 27, 336-341 (1997)

Chen P, Mayne M, Power C, Nath A. The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases. J Biol Chem 272, 22385-22388 (1997)

Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9, 1586-1597 (1995)

Clavel F, Guyader M, Guetard D, Salle M, Montagnier L, Alizon M. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 324, 691-695 (1986)

Confalonieri F, Duguet M. A. 200-amino acid ATPase module in search of a basic function. Bioessays 17, 639-650 (1995)

[Seite 41↓]

Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, Rock KL. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 272, 13437-13445 (1997)

Dal Maso L, Serraino D, Franceschi S. Epidemiology of HIV-associated malignancies . Cancer Treat Res 104, 1-18 (2001)

de Baar MP, van Dooren MW, de Rooij E, Bakker M, van Gemen B, Goudsmit J, de Ronde. A.Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. J. Clin Microbiol 39, 1378-1384 (2001)

Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M. Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1. J Virol 70, 4427-4437 (1996)

Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol 82, 1807-1814 (2001)

Dubiel W, Pratt G, Ferrell K, Rechsteiner M. Purification of an 11 S regulator of the multicatalytic protease. J Biol Chem 267, 22369-22377 (1992)

Dubiel W, Ferrell K, Rechsteiner M. Peptide sequencing identifies MSS1, a modulator of HIV Tat-mediated transactivation, as subunit 7 of the 26 S protease. FEBS Lett 323, 276-278 (1993)

Dick TP, Ruppert T, Groettrup M, Kloetzel PM, Kuehn L, Koszinowski UH, Stevanovic S, Schild H, Rammensee HG. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86, 253-262 (1996)

Ehret A, Li-Weber M, Frank R, Krammer PH. The effect of HIV-1 regulatory proteins on cellular genes: derepression of the IL-2 promoter by Tat. Eur J Immunol 31, 1790-1799 (2001)

Elliott T, Willis A, Cerundolo V, Townsend A. Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum. J Exp Med 181, 1481-1491 (1995)

Endo S, Kubota S, Siomi H, Adachi A, Oroszlan S, Maki M, Hatanaka M. A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization . Virus Genes 3, 99-110 (1989)

Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P, Theodorou I, Combadiere C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287, 2274-2277 (2000)

Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 91, 664-668 (1994)

Frankel AD. Activation of HIV transcription by Tat. Curr Opin Genet Dev 2, 293-298 (1992)

Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264-267 (1993)

Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A 96, 8324-8326 (1999)

Gelmann EP, Franchini G, Manzari V, Wong-Staal F, Gallo RC. Molecular cloning of a unique human T-cell leukemia virus (HTLV-IIMo). Proc Natl Acad Sci U S A 81, 993-997 (1984)

Gille C, Goede A, Preissner R, Rother K, Frommel C. Conservation of substructures in proteins: interfaces of secondary structural elements in proteasomal subunits. J Mol Biol 299, 1147-1154 (2000)

Grand RJ, Turnell AS, Mason GG, Wang W, Milner AE, Mymryk JS, Rookes SM, Rivett AJ, Gallimore PH. Adenovirus early region 1A protein binds to mammalian SUG1-a regulatory component of the proteasome. Oncogene 18, 449-458 (1999)

Gray CW, Slaughter CA, DeMartino GN. PA28 activator protein forms regulatory caps on proteasome stacked rings. J Mol Biol 236, 7-15 (1994)

[Seite 42↓]

Groettrup M, Kraft R, Kostka S, Standera S, Stohwasser R, Kloetzel PM. A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol 26, 863-869 (1996)

Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, Rammensee HG, Koszinowski UH, Kloetzel PM. A role for the proteasome regulator PA28alpha in antigen presentation. Nature 381, 166-168 (1996)

Groettrup M, Soza A, Kuckelkorn U, Kloetzel PM. Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today 17, 429-435 (1996)

Gu Y, Wu RF, Xu YC, Flores SC, Terada LS. HIV Tat activates c-Jun amino-terminal kinase through an oxidant-dependent mechanism. Virology 286, 62-71 (2001)

Hauber J, Malim MH, Cullen BR. Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol 63, 1181-1187 (1989)

Hendil KB, Khan S, Tanaka K. Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. Biochem J 332, 749-754 (1998)

Hiller MM, Finger A, Schweiger M, Wolf DH. ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science 273, 1725-1728 (1996)

Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8, 67-113 (1992)

Howcroft TK, Strebel K, Martin MA, Singer DS. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 260, 1320-1322 (1993)

Hu Z, Zhang Z, Doo E, Coux O, Goldberg AL, Liang TJ. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J Virol 73, 7231-7240 (1999)

Huang LM, Joshi A, Willey R, Orenstein J, Jeang KT. Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity. EMBO J 13, 2886-2896 (1994)

Jakobovits A, Smith DH, Jakobovits EB, Capon DJ. A discrete element 3' of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator. Mol Cell Biol 8, 2555-2561 (1988)

Jariel-Encontre I, Pariat M, Martin F, Carillo S, Salvat C, Piechaczyk M. Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome. J Biol Chem 270, 11623-11627 (1995)

Jeang KT, Gatignol A. Comparison of regulatory features among primate lentiviruses. Curr Top Microbiol Immunol 188, 123-144 (1994)

Jonathan EC, Bernhard EJ, McKenna WG. How does radiation kill cells? Curr Opin Chem Biol 3 , 77-83 (1999)

Karin M, Liu Zg, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 9, 240-246 (1997)

Kellogg JA, Atria PV, Sanders JC, Eyster ME. Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0. Clin Diagn Lab Immunol 8 , 560-563 (2001)

Kelly A, Powis SH, Glynne R, Radley E, Beck S, Trowsdale J. Second proteasome-related gene in the human MHC class II region. Nature 353, 667-668 (1991)

Kelly GD, Morris CB, Offermann MK. Lack of responsiveness of a nuclear factor-kappaB-regulated promoter to transactivation by human immunodeficiency virus 1 Tat in HeLa cells. Virology 263, 128-138 (1999)

Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2, 179-187 (2001)

Knowlton JR, Johnston SC, Whitby FG, Realini C, Zhang Z, Rechsteiner M, Hill CP. Structure of the proteasome activator REGalpha (PA28alpha). Nature 390, 639-643 (1997)

[Seite 43↓]

Kopp F, Dahlmann B, Hendil KB. Evidence indicating that the human proteasome is a complex dimer. J Mol Biol 229, 14-19 (1993)

Knuehl C, Spee P, Ruppert T, Kuckelkorn U, Henklein P, Neefjes J, Kloetzel PM. The murine cytomegalovirus pp89 immunodominant H-2Ld epitope is generated and translocated into the endoplasmic reticulum as an 11-mer precursor peptide. J Immunol Aug 167, 1515-1521 (2001)

Kuehn L, Dahlmann B. Reconstitution of proteasome activator PA28 from isolated subunits: optimal activity is associated with an alpha,beta-heteromultimer. FEBS Lett 394, 183-186 (1996)

Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard JM, Schwartz O. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8, 483-495 (1998)

Lehner PJ, Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol 8, 59-67 (1996)

Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Structural features of 26S and 20S proteasomes. Enzyme Protein 47, 252-273 (1993)

Ma CP, Slaughter CA, DeMartino GN. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J Biol Chem 267, 10515-10523 (1992)

Manna SK, Aggarwal BB. Differential requirement for p56lck in HIV-tat versus TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal kinase, and apoptosis . J Immunol 164, 5156-5166 (2000)

Marzio G, Tyagi M, Gutierrez MI, Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci U S A 95, 13519-13524 (1998)

Mischiati C, Pironi F, Milani D, Giacca M, Mirandola P, Capitani S, Zauli G. Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK pathways in CD4 T cells. AIDS 13, 1637-1645 (1999)

Momburg F, Hammerling GJ. Generation and TAP-mediated transport of peptides for major histocompatibility complex class I molecules. Adv Immunol 68, 191-256 (1998)

Naumann M, Bech-Otschir D, Huang X, Ferrell K, Dubiel W. COP9 signalosome-directed c-Jun activation/stabilization is independent of JNK. J Biol Chem 274, 35297-35300 (1999)

Nelbock P, Dillon PJ, Perkins A, Rosen CA. A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator. Science 248, 1650-1653 (1990)

New DR, Maggirwar SB, Epstein LG, Dewhurst S, Gelbard HA. HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NFkappaB-independent mechanism. J Biol Chem 273, 17852-17858 (1998)

Nikaido T, Shimada K, Shibata M, Hata M, Sakamoto M, Takasaki Y, Sato C, Takahashi T, Nishida Y. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus. Clin Exp Immunol 79, 209-214 (1990)

Orlowski M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry 29 , 10289-10297 (1990)

Orlowski M. The multicatalytic proteinase complex (proteasome) and intracellular protein degradation: diverse functions of an intracellular particle. J Lab Clin Med 121, 187-189 (1993)

Ortiz-Navarrete V, Seelig A, Gernold M, Frentzel S, Kloetzel PM, Hammerling GJ. Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 353, 662-664 (1991)

Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78, 773-785 (1994)

[Seite 44↓]

Pamer EG. Direct sequence identification and kinetic analysis of an MHC class I-restricted Listeria monocytogenes CTL epitope. J Immunol 152, 686-694 (1994)

Peters JM, Cejka Z, Harris JR, Kleinschmidt JA, Baumeister W. Structural features of the 26 S proteasome complex. J Mol Biol 234, 932-937 (1993)

Preissner R, Goede A, Frommel C. Dictionary of interfaces in proteins (DIP). Data bank of complementary molecular surface patches. J Mol Biol 280, 535-550 (1998)

Preissner R, Goede A, Frommel C. Homonyms and synonyms in the Dictionary of Interfaces in Proteins (DIP). Bioinformatics 15, 832-836 (1999)

Rana TM, Jeang KT. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch Biochem Biophys 365, 175-185 (1999)

Realini C, Dubiel W, Pratt G, Ferrell K, Rechsteiner M. Molecular cloning and expression of a gamma-interferon-inducible activator of the multicatalytic protease. J Biol Chem 269, 20727-20732 (1994)

Rechsteiner M, Realini C, Ustrell V. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J 345, 1-15 (2000)

Rivett AJ. The multicatalytic proteinase. Multiple proteolytic activities. J Biol Chem 264, 12215-12219 (1989)

Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761-771 (1994)

Rousset R, Desbois C, Bantignies F, Jalinot P. Effects on NF-kappa B1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome. Nature 381, 328-331 (1996)

Saloojee H, Violari A. Regular review: HIV infection in children. BMJ 323, 670-674 (2001)

Schubert U, Anton LC, Bacik I, Cox JH, Bour S, Bennink JR, Orlowski M, Strebel K, Yewdell JW. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol 72, 2280-2288 (1998)

Seeger M, Ferrell K, Frank R, Dubiel W. HIV-1 tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation. J Biol Chem 272, 8145-8148 (1997)

Seufert W, Futcher B, Jentsch S. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 373, 78-81 (1995)

Shibuya H, Irie K, Ninomiya-Tsuji J, Goebl M, Taniguchi T, Matsumoto K. New human gene encoding a positive modulator of HIV Tat-mediated transactivation. Nature 357, 700-702 (1992)

Shimbara N, Nakajima H, Tanahashi N, Ogawa K, Niwa S, Uenaka A, Nakayama E, Tanaka K. Double-cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region. Genes Cells 2, 785-800 (1997)

Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B . Annu Rev Cell Biol 10 , 405-455 (1994)

Sijts AJ, Ruppert T, Rehermann B, Schmidt M, Koszinowski U, Kloetzel PM. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med 191 , 503-514 (2000)

Song X, Mott JD, von Kampen J, Pramanik B, Tanaka K, Slaughter CA. A model for the quaternary structure of the proteasome activator PA28. Biol Chem 271 , 26410-26417 (1996)

Stoltze L, Nussbaum AK, Sijts A, Emmerich NP, Kloetzel PM, Schild H. The function of the proteasome system in MHC class I antigen processing. Immunol Today 21 , 317-319 (2000)

Tanaka K, Tanahashi N, Tsurumi C, Yokota KY, Shimbara N. Proteasomes and antigen processing. Adv Immunol 64 , 1-38 (1997)

[Seite 45↓]

Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 14 , 2876-2883 (1995)

Treier M, Staszewski LM, Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78 , 787-798 (1994)

Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272 , 16010-16017 (1997)

Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, Krammer PH, Droge W, Lehmann V. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J 14 , 546-554 (1995)

Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, Hill CP. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408 , 115-120 (2000)

Yamey G, Rankin W, Feachem R. Twenty years of AIDS, and no end in sight. A BMJ theme issue will refocus attention on this catastrophic epidemic. BMJ 322 , 1440-1444 (2001)

Yoshimura T, Kameyama K, Takagi T, Ikai A, Tokunaga F, Koide T, Tanahashi N, Tamura T, Cejka Z, Baumeister W. Molecular characterization of the "26S" proteasome complex from rat liver . J Struct Biol 111 , 200-211 (1993)

Zhang Z, Clawson A, Realini C, Jensen CC, Knowlton JR, Hill CP, Rechsteiner M. Identification of an activation region in the proteasome activator REGalpha . Proc Natl Acad Sci U S A 95 , 2807-2811 (1998)

[Seite 46↓]


Propper C, Huang X, Roth J, Sorg C, Nacken W. Analysis of the MRP8-MRP14 protein-protein interaction by the two-hybrid system suggests a prominent role of the C-terminal domain of S100 proteins in dimer formation. J Biol Chem 274 , 183-188 (1999)

Naumann M, Bech-Otschir D, Huang X, Ferrell K, Dubiel W. COP9 signalosome-directed c-Jun activation/stabilization is independent of JNK. J Biol Chem 274 , 35297-35300 (1999)

Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, Dubiel W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20 , 1630-1639 (2001)

Pollmann C, Huang H, Mail J, Bech-Otschir D, Naumann M, Dubiel W. The Constitutive Photomorgenesis 9 Signalosome Directs Vascular Endothelial Growth Factor Production in Tumor Cells. Cancer Research 61 , 1630-1639 (2001)

Huang, X, Seifert U, Salzmann U, Sijts E, Henklein, Preißner R, Henke W, Kloetzel PM, Dubiel W. The HIV-1 Tat Protein suppresses 11S regulator/PA28-dependent antigen presentation. Proc Natl Acad Sci USA , submitted

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: